2011

Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, Biswas S, Poulton I, Prieur E, Correa S, Rowland R, Lang T, Williams J, Gilbert SC, Sinden RE, Todryk S, Hill AV. A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine 2011 Oct 6;29(43):7514-22. Epub 2011 16 Apr. (FP9 PP and MVA PP)

Mark J. GeelsEgeruan Babatunde ImoukhuedeNathalie ImbaultHarry van Schooten, Terry McWade, Marita Troye-Blomberg, Roland Dobbelaer, Alister G. Craig, Odile Leroy. European Vaccine Initiative: lessons from developing malaria vaccines. Expert Reviews Vaccines 2011, vol. 10 (12) 1697 - 1708

Regitze L Thogersen, Anthony A Holder, Adrian VS Hill, David E Arnot, Egeruan B ImoukhuedeOdile Leroy. Comparative decline in funding of European Commission malaria vaccine projects: what next for the European scientists working in this field? Malaria Journal 2011, 10:255 doi:10.1186/1475-2875-10-255

Sabine Bélard, Saadou Issifou, Aurore B. Hounkpatin, Frieder Schaumburg, Ulysse Ateba Ngoa, Meral Esen, Rolf Fendel, Pablo Martinez de Salazar, Raymund E. Mürbeth, Paul Milligan, Nathalie ImbaultEgeruan Babatunde Imoukhuede, Michael Theisen, Søren Jepsen, Ramadhani A. Noor, Brenda Okech, Peter G. Kremsner, Benjamin Mordmüller. A Randomised Controlled Phase Ib Trial of the Malaria Vaccine Candidate GMZ2 in African Children. PLoS One, July 2011, vol. 6, issue 7 (GMZ2)

Ebensen T, Libanova R, Schulze K, Yevsa T, Morr M, Guzmán CA.  Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant.Vaccine. 2011 Jul 18;29(32):5210-20. doi: 10.1016/j.vaccine.2011.05.026. Epub 2011 May 25 (TRANSVAC)

N. Collin and P. M. Dubois. The Vaccine Formulation Laboratory: A platform for access to adjuvants. Vaccine 2011 Jul, Vol. 29 supplement, A37-39 (TRANSVAC)

N. D. Huntington, N. L. Alves, N. Legrand, A. Lim, H. Strick-Marchand, JJ. Mention, A. Plet, K. Weijer, Y. Jacques, P. D. Becker, C. Guzman, P. Soussan, D. Kremsdorf, H. Spits, and J. P. Di Santo.  IL-15 transpresentation promotes both human T-cell reconstitution and T-cell–dependent antibody responses in vivo, PNAS, 2011, 108 (15) 6217 - 6222 (TRANSVAC)

Chiacchio T, Petruccioli E, Vanini V, Butera O, Cuzzi G, Petrone L, Matteucci G, Lauria FN, Franken KL, Girardi E, Ottenhoff TH, Goletti D. Higher frequency of T-cell response to M. tuberculosis latency antigen Rv2628 at the site of active tuberculosis disease than in peripheral blood. PLoS One. 2011; 6(11):e27539 (IDEA)

Agnes Kisser, Ulrich Heininger, Vasee S. Moorthy, Bartholomew D. Akanmori and Odile Leroy: Addressing the needs and gaps in safety assessment of vaccines during clinical trials in resource limited countries. Vaccine (Epub 16 April 2011), doi:10.1016/j.vaccine.2011.03.008

Kwadwo A Kusi, Bart W Faber, Marjolein van der Eijk, Alan W Thomas, Clemens HM Kocken, Edmond J Remarque.  Immunization with different Pf AMA1 alleles in sequence induces clonal imprint humoral responses that are similar to responses induced by the same alleles as a vaccine cocktail in rabbits.  Malaria Journal 2011 Feb. 10:40 DOI:10.1186/1475-2875-10-40 (AMA1-DiCo and EMVDA)

OPTIMALVAC Consortium: Towards validated assays for key immunological outcomes
Vaccine (Epub 4 Feb 2011), DOI: doi:10.1016/j.vaccine.2011.01.070 (OPTIMALVAC)